PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Academic Article uri icon

Overview

abstract

  • Efforts to limit GVHD mediated by alloreactive donor T cells after allogeneic bone marrow transplantation are limited by a concomitant decrease in graft-versus-tumor (GVT) activity and increased possibilities of tumor relapse. Using a novel approach, we adoptively transferred conventional T cells expressing the transcription factor promyelocytic leukemia zinc finger (PLZF), which confers effector properties resembling invariant natural killer T cells, such as copious production of cytokines under suboptimal stimulation. PLZF expression in T-cell allografts attenuates expansion of alloreactive T cells, leading to lower GVHD. Intact alloreactivity-driven antitumor cytokine responses result in preserved GVT effects, leading to improved survival. Our findings suggest that therapy with PLZF-overexpressing T cells would result in overall improved outcomes due to less GVHD and intact GVT effects.

publication date

  • June 3, 2013

Research

keywords

  • Graft vs Host Disease
  • Graft vs Tumor Effect
  • Kruppel-Like Transcription Factors
  • Neoplasms, Experimental
  • T-Lymphocytes

Identity

PubMed Central ID

  • PMC3732814

Scopus Document Identifier

  • 84881423119

Digital Object Identifier (DOI)

  • 10.1158/0008-5472.CAN-12-4699

PubMed ID

  • 23733752

Additional Document Info

volume

  • 73

issue

  • 15